The ICH QSEM framework — covering Quality, Safety, Efficacy and Multidisciplinary guidelines — provides global standards that B.Pharm students must master for pharmaceutical development, regulatory submissions and manufacturing. This overview emphasizes the Q-series (quality) guidelines: stability (Q1), analytical validation (Q2), impurities (Q3), pharmaceutical development and quality risk management (Q8–Q10), biotechnological products (Q5), and lifecycle management (Q12). Clear understanding of stability testing, impurity control, validation parameters, GMP for APIs, QRM and pharmaceutical quality systems is essential for formulators, analysts and QA professionals. The following targeted, concept-driven MCQs reinforce core principles and practical applications of ICH Q-series guidelines. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. Which word best describes the primary focus of the ICH Q-series guidelines?
- Safety assessment of clinical trials
- Quality aspects of drug development and manufacture
- Marketing and labeling requirements
- Pharmacovigilance reporting systems
Correct Answer: Quality aspects of drug development and manufacture
Q2. ICH Q1 guidelines are mainly concerned with which topic?
- Analytical method validation
- Stability testing of new drug substances and products
- Specification setting for impurities
- Good manufacturing practice for APIs
Correct Answer: Stability testing of new drug substances and products
Q3. ICH Q2(R1) primarily provides guidance on:
- Conducting clinical efficacy studies
- Analytical method validation parameters and procedures
- Environmental risk assessment for APIs
- Post-approval change management
Correct Answer: Analytical method validation parameters and procedures
Q4. Which ICH guideline series specifically addresses impurities including residual solvents?
- Q5 series
- Q3 series
- Q8 series
- Q10 series
Correct Answer: Q3 series
Q5. ICH Q5 deals mainly with which category of products?
- Over-the-counter (OTC) small-molecule drugs
- Biotechnological/biological products
- Cosmetics and excipients
- Veterinary medicines
Correct Answer: Biotechnological/biological products
Q6. Which guideline focuses on Good Manufacturing Practice for active pharmaceutical ingredients (APIs)?
- Q6: Specifications
- Q7: GMP for APIs
- Q9: Quality Risk Management
- Q12: Post-approval changes
Correct Answer: Q7: GMP for APIs
Q7. ICH Q8 is best described as guidance on:
- Marketing authorization procedures
- Pharmaceutical development and Quality by Design principles
- Adverse event reporting timelines
- Environmental impact assessment
Correct Answer: Pharmaceutical development and Quality by Design principles
Q8. The core objective of ICH Q9 is to provide principles for:
- Analytical method transfer
- Quality risk management throughout product lifecycle
- Clinical trial design
- Labeling and package information
Correct Answer: Quality risk management throughout product lifecycle
Q9. ICH Q10 outlines expectations for a company’s:
- Clinical pharmacology program
- Pharmaceutical quality system (PQS) and lifecycle management
- Marketing strategy for global registration
- Cost analysis for manufacturing
Correct Answer: Pharmaceutical quality system (PQS) and lifecycle management
Q10. Which Q guideline specifically addresses development and manufacture of drug substances?
- Q1A
- Q11
- Q3B
- Q6A
Correct Answer: Q11
Q11. ICH Q12 primarily provides guidance on:
- Clinical trial data standardization
- Lifecycle management and post-approval changes for pharmaceuticals
- Analytical method validation
- Radiopharmaceuticals safety
Correct Answer: Lifecycle management and post-approval changes for pharmaceuticals
Q12. Which document would you consult for setting test procedures and acceptance criteria for a drug substance?
- Q3D: Elemental Impurities
- Q6A: Specifications
- Q5C: Viral safety
- Q8(R2): Pharmaceutical Development
Correct Answer: Q6A: Specifications
Q13. Which of the following is NOT typically a validation parameter defined in ICH Q2?
- Accuracy
- Precision
- Sterility
- Linearity
Correct Answer: Sterility
Q14. The purpose of forced degradation studies in the context of ICH Q1 and Q2 is to:
- Determine the manufacturing yield of a process
- Establish a stability-indicating analytical method and identify degradation pathways
- Assess patient acceptance of dosage form
- Measure extractables and leachables from packaging
Correct Answer: Establish a stability-indicating analytical method and identify degradation pathways
Q15. Which stress conditions are normally included in forced degradation testing?
- Hydrolysis, oxidation, photolysis and thermal stress
- Microbial challenge, patient skin irritation, palatability
- Only long-term storage at 5°C
- Packaging drop tests and compression strength
Correct Answer: Hydrolysis, oxidation, photolysis and thermal stress
Q16. The main intent of ICH QRM (Q9) in pharmaceutical quality is to:
- Replace all stability testing
- Provide a systematic process to assess, control and communicate risks to quality
- Define labeling requirements
- Describe clinical trial endpoints
Correct Answer: Provide a systematic process to assess, control and communicate risks to quality
Q17. Which risk assessment tool is commonly promoted under ICH Q9?
- FMEA (Failure Mode and Effects Analysis)
- ANOVA statistical test
- Clinical endpoint scoring
- Cost–benefit financial model
Correct Answer: FMEA (Failure Mode and Effects Analysis)
Q18. Which guideline specifically addresses residual solvents and their permissible limits?
- Q3C: Impurities––Residual Solvents
- Q5A: Viral Safety
- Q6B: Stability Requirements
- Q10: Pharmaceutical Quality System
Correct Answer: Q3C: Impurities––Residual Solvents
Q19. Bracketing and matrixing designs recommended in ICH stability guidance are used to:
- Speed up analytical method validation
- Reduce the number of samples and testing requirements while still providing stability information
- Determine clinical dosing regimens
- Assess impurity thresholds for genotoxic compounds
Correct Answer: Reduce the number of samples and testing requirements while still providing stability information
Q20. Under ICH Q3B, impurity qualification is primarily based on:
- Marketing price of the drug
- Potential toxicity and the level of the impurity in the drug product
- Color and odor of the impurity
- Patient preference surveys
Correct Answer: Potential toxicity and the level of the impurity in the drug product
Q21. Which element is a key component of a Pharmaceutical Quality System as described in ICH Q10?
- CAPA (Corrective and Preventive Actions)
- Formulation aesthetics
- Advertising budget allocation
- Clinical site selection criteria
Correct Answer: CAPA (Corrective and Preventive Actions)
Q22. For biologics, which ICH Q guidance provides comparability considerations after manufacturing changes?
- Q2 Validation
- Q5E Comparability of Biotechnological Products
- Q3D Elemental Impurities
- Q8 Pharmaceutical Development
Correct Answer: Q5E Comparability of Biotechnological Products
Q23. Which of the following best describes a stability-indicating method?
- An assay that measures only the parent drug without resolving degradation products
- An analytical method that accurately and precisely separates and quantifies the drug from its degradation products
- A sensory test to evaluate tablet taste
- A packaging compatibility test
Correct Answer: An analytical method that accurately and precisely separates and quantifies the drug from its degradation products
Q24. In the context of ICH Q8, Quality by Design (QbD) emphasizes:
- Fixed one-time approach with no post-approval changes
- Understanding formulation and process variables to design quality into the product
- Only using traditional “one-factor-at-a-time” experiments
- Eliminating the need for validation
Correct Answer: Understanding formulation and process variables to design quality into the product
Q25. Which ICH guideline series is explicitly described as “Multidisciplinary” in the QSEM grouping?
- Q-series only
- M (Multidisciplinary) guidelines
- S (Safety) series
- E (Efficacy) series
Correct Answer: M (Multidisciplinary) guidelines
Q26. Which activity is essential when establishing specifications according to ICH Q6A?
- Justifying test methods and acceptance criteria using development, manufacturing and stability data
- Setting arbitrary limits based on competitor products
- Using only historical values without current validation
- Relying solely on supplier certificates without in-house testing
Correct Answer: Justifying test methods and acceptance criteria using development, manufacturing and stability data
Q27. Which of the following is a primary benefit of applying ICH Q9 risk management to analytical control strategy?
- Completely eliminating in-process controls
- Prioritizing resources to control critical analytical risks and improve decision making
- Replacing stability studies with risk registers
- Reducing regulatory submissions
Correct Answer: Prioritizing resources to control critical analytical risks and improve decision making
Q28. ICH Q3D focuses on which type of impurity control?
- Organic impurities in tablets
- Elemental (metal) impurities and their safety-based limits
- Microbial limits for sterile products
- Degradation products formed during photostability testing
Correct Answer: Elemental (metal) impurities and their safety-based limits
Q29. Which statement best reflects the scope of ICH Q11?
- Guidance on the global harmonization of clinical endpoints
- Guidance on the development and manufacture of drug substances including chemical and biological entities
- Requirements for advertising pharmaceutical products
- Guidance solely on container closure systems
Correct Answer: Guidance on the development and manufacture of drug substances including chemical and biological entities
Q30. Under ICH Q10, management responsibilities include which of the following?
- Ensuring a robust pharmaceutical quality system, including management review and continual improvement
- Approving all marketing campaigns
- Designing clinical trial protocols
- Determining pricing strategies for markets
Correct Answer: Ensuring a robust pharmaceutical quality system, including management review and continual improvement
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com